title: Effects of the oral converting enzyme inhibitor, SQ 14225, in a model of low cardiac output in dogs.
abstract: Dogs with thoracic caval constriction retain sodium and develop ascites and edema. The role of the renin-angiotensin-aldosterone system in this model of low output failure was evaluated before, during, and after administration of the new orally active converting enzyme inhibitor, 2-D-methyl-3-mercaptopropanoyl-L-proline (SQ 14225). The acute response to the initial oral dose of SQ 14225 (10 mg/kg) consisted of a striking fall in plasma aldosterone concentration (PAC) from 22.7 and 29.9 ng% to 10.7, 11.9, and 11.0 ng% (P less than 0.05) after 67.5, 112.5, and 157.5 minutes; sodium excretion increased from 1.9 and 1.9 mu Eq/min to 19.9, 22.4, and 17.8 mu Eq/min. Arterial pressure and filtration fraction decreased (P less than 0.05), and plasma renin activity (PRA) increased (P less than 0.05) after the initial dose of SQ 14225; clearance of paraaminohippuric acid (PAH) and creatinine did not change significantly. The daily responses for 3-4 days to SQ 14225 (35 mg/kg per day, given as doses of 10, 10, and 15 mg/kg) were a decrease in PAC from 50 +/- 15 and 32 +/- 10 ng% to 10 +/- 4 ng% on the 4th day, a value not statistically different from normal (P greater than 0.05), and an increase in sodium excretion from 2.9 to 2.0 mEq/day to 5.7, 10.0, 32.4, and 32.9 mEq/day on a sodium intake of 35 mEq/day (P less than 0.05 for the last 2 days). Arterial pressure and creatinine clearance decreased (P less than 0.05). PRA increased transiently on day 1 of SQ 14225 and then returned toward control levels, and clearance of PAH was unchanged. These data demonstrate an important role for aldosterone and the renin-angiotensin system in the retention of sodium and in ascites formation in dogs with thoracic caval constriction.
mesh_terms: D000284:Administration, Oral; D000450:Aldosterone / Q000097:blood / Q000502:physiology*; D000804:Angiotensin II / Q000502:physiology*; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D001201:Ascites / Q000209:etiology / Q000503:physiopathology; D001794:Blood Pressure; D002302:Cardiac Output; D003250:Constriction; D003404:Creatinine / Q000378:metabolism; D004195:Disease Models, Animal; D004285:Dogs; D004487:Edema / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006333:Heart Failure / Q000503:physiopathology*; D007668:Kidney / Q000503:physiopathology; D011392:Proline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D012083:Renin / Q000097:blood / Q000502:physiology*; D012964:Sodium / Q000378:metabolism / Q000652:urine; D014683:Vena Cava, Superior / Q000601:surgery; D010130:p-Aminohippuric Acid / Q000378:metabolism
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II; D000450:Aldosterone; D011392:Proline; D012964:Sodium; D003404:Creatinine; D012083:Renin; D010130:p-Aminohippuric Acid